Evidence map›Paper›PMID 33737618›Full record

ArticleScientific reports2021

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.

Maiko Abumiya, Naoto Takahashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Clinical Spectrum of Bosutinib Related Side Effects in a Patient of CML: A Case Report and Review of Literature.International journal of hematology-oncology and stem cell research · 2025
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maiko AbumiyaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Saori TakahashiClinical Research Promotion and Support Center, Akita University Hospital, Akita, Japan.
Tomoko YoshiokaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Yoshihiro KameokaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan. m-miura@hos.akita-u.ac.jp.
Akita University · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C

Indexed as

AdultAgedAged, 80 and overAniline CompoundsBiomarkers, PharmacologicalCreatinineFemaleGenotypeGlomerular Filtration RateHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNitrilesOrganic Cation Transporter 2Polymorphism, Single NucleotideAniline CompoundsBiomarkers, PharmacologicalbosutinibCreatinineNitrilesOrganic Cation Transporter 2QuinolinesSLC22A2 protein, human

Identifiers

PMID33737618
PMCPMC7973796
OpenAlexW3138334617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.